Key Highlights
- 2.5% is the gap between AbbVie (NYSE:ABBV) at USD 284.21 and its 52-week high of USD 291.40, per published market data on October 16, 2026 intraday. The RSI is 70.5, above the 70 overbought threshold, and the market value is USD 502.23 billion.
- USD 0.11 per share is the third quarter effect of USD 216 million of acquired IPR&D and milestones expense, per the 8-K dated October 5, 2026. It cut AbbVie (NYSE:ABBV) full-year adjusted EPS guidance to USD 13.76 to USD 13.96 from USD 13.87 to USD 14.07.
- USD 8.030 billion was second quarter Skyrizi and Rinvoq revenue, 47.3% of USD 16.990 billion total net revenues (own arithmetic), per the July 31, 2026 release. Skyrizi rose 24.4%, Rinvoq 24.5%, and Humira fell 35.9% for AbbVie (NYSE:ABBV).
- USD 6.92 is the annual dividend, a 2.4% yield at USD 284.21 (own arithmetic), after an October 15 ex-dividend date reported in published data. AbbVie (NYSE:ABBV) reports third quarter results on October 30, 2026 before the open, per published market calendars.
Price Action and Valuation Context
AbbVie (NYSE:ABBV) rose 0.29% to USD 284.21 on October 16, 2026 per published market data, on relative volume of 0.2x early in the session. The shares were USD 260.69 on September 3, 2026, so they are up 9.0% since then (own arithmetic). On the guidance midpoint of USD 13.86, the forward multiple is 20.5 times (own arithmetic). An RSI above 70 can precede mean reversion.
Guidance Reset and Segment Drivers
The October 5, 2026 8-K did not name the transaction behind the USD 216 million expense. Acquired IPR&D is expensed at once, so deal costs reduce EPS the quarter they occur, and guidance excludes such costs until incurred. Third quarter EPS guidance fell to USD 3.73 to USD 3.77 from USD 3.84 to USD 3.88. Second quarter adjusted EPS was USD 3.65, up 22.9%. Neuroscience revenue rose 20.3% to USD 3.228 billion, while oncology fell 1.5%. The proposed Apogee Therapeutics (NASDAQ:APGE) acquisition, at USD 10.9 billion of equity value, was expected to close in the third quarter; completion was not confirmed in the material reviewed.
Tariffs, Pipeline, Analysts and Risks
A 100% Section 232 tariff on patented drugs was announced in April 2026, with 15% for the European Union, Japan, Korea and Switzerland, and reduced rates for onshoring plans. AbbVie tariff exposure is not disclosed in the material reviewed. Skyrizi beat placebo in Phase 3 Crohn's disease data reported the week of October 12, and the FDA granted two Breakthrough Therapy Designations to telisotuzumab adizutecan on October 8. Morgan Stanley holds a USD 310 target, Bank of America USD 305 and UBS USD 275. Humira erosion and more deal charges are the specific risks.
Where Things Stand
The IPR&D charge is an accounting expense, not weaker demand. AbbVie (NYSE:ABBV) trades 2.5% below USD 291.40 after USD 0.11 of that expense lowered guidance, while Skyrizi grew 24.4%, Rinvoq 24.5% and neuroscience 20.3%. The offsets are a USD 502.23 billion market value, an RSI of 70.5, 20.5 times forward EPS and unquantified tariff exposure. UBS at USD 275 sits below the price, Morgan Stanley at USD 310 above. The next catalyst is the October 30, 2026 report, where Humira erosion and further deal charges matter.





_11_13_2026_20_30_45_840725.jpg)
Please wait processing your request...